Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Literature
1.
Notake T, Kobayashi A, Shinkawa H et al (2017) Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection. Int J Clin Oncol. doi:10.​1007/​s10147-017-1114-1
2.
Greenland S, Mansournia MA, Altman DG (2016) Sparse data bias: a problem hiding in plain sight. BMJ 352:i1981CrossRefPubMed
3.
Ayubi E, Safiri S (2017) Lateral lymph node recurrence after total thyroidectomy and central neck dissection in patients with papillary thyroid cancer without clinical evidence of lateral neck metastasis: Comment on data sparsity. Oral Oncol. doi:10.​1016/​j.​oraloncology.​2017.​04.​006
4.
Steyerberg E (2008) Clinical prediction models: a practical approach to development, validation, and updating. Springer Science & Business Media, New York
5.
Jewell NP (2003) Statistics for epidemiology. CRC Press, Boca Raton
6.
Ayubi E, Safiri S (2017) Profile and outcome of first 109 cases of paediatric acute liver failure at a specialized paediatric liver unit in India: Methodological issues. Liver Int. doi:10.​1111/​liv.​13455 PubMed
Metadata
Title
Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection: methodological issues
Authors
Erfan Ayubi
Saeid Safiri
Publication date
01-08-2017
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1127-9

Other articles of this Issue 4/2017

International Journal of Clinical Oncology 4/2017 Go to the issue

Original Article

Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan

Original Article

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan

Original Article

Overall survival and prognostic factors in patients with spinal metastases from lung cancer treated with and without epidermal growth factor receptor tyrosine kinase inhibitors

Invited Review Article

Targeting DNA repair and replication stress in the treatment of ovarian cancer

Review Article

Targeting metabolic reprogramming in KRAS-driven cancers

Review Article

Biphasic malignant tumours of the abdominal cavity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits